Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.

Lung Cancer. 2013 Mar;79(3):283-8. doi: 10.1016/j.lungcan.2012.11.007. Epub 2012 Dec 14.

2.

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K.

Lung Cancer. 2015 Dec;90(3):477-83. doi: 10.1016/j.lungcan.2015.09.025. Epub 2015 Oct 9.

PMID:
26604031
3.

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.

Tudor RA, D'Silva A, Tremblay A, MacEachern P, Morris D, Brenner D, Kopciuk K, Bebb DG.

PLoS One. 2017 Aug 4;12(8):e0181867. doi: 10.1371/journal.pone.0181867. eCollection 2017.

4.

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

AJR Am J Roentgenol. 2013 Jul;201(1):W64-71. doi: 10.2214/AJR.12.9668.

5.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
6.

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.

Cancer. 2013 Nov 1;119(21):3761-8. doi: 10.1002/cncr.28290. Epub 2013 Aug 6.

7.

Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies.

Uozu S, Imaizumi K, Yamaguchi T, Goto Y, Kawada K, Minezawa T, Okamura T, Akao K, Hayashi M, Isogai S, Okazawa M, Hashimoto N, Hasegawa Y.

BMC Pulm Med. 2017 Dec 6;17(1):175. doi: 10.1186/s12890-017-0514-3.

8.

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.

Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M.

J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7.

9.
10.

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.

Hong SH, Kim YS, Lee JE, Kim IH, Kim SJ, Han D, Yoo IeR, Chung YG, Kim YH, Lee KY, Kang JH.

Cancer Res Treat. 2016 Jul;48(3):1110-9. doi: 10.4143/crt.2015.289. Epub 2016 Jan 6.

11.

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

Auliac JB, Fournier C, Audigier Valette C, Perol M, Bizieux A, Vinas F, Decroisette Phan van Ho C, Bota Ouchlif S, Corre R, Le Garff G, Fournel P, Baize N, Lamy R, Vergnenegre A, Arpin D, Marin B, Chouaid C, Gervais R.

Target Oncol. 2016 Apr;11(2):167-74. doi: 10.1007/s11523-015-0387-4.

PMID:
26315967
12.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.

Anticancer Res. 2015 Jul;35(7):3885-91.

PMID:
26124334
13.

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF.

Eur J Cancer. 2011 Nov;47(17):2603-6. doi: 10.1016/j.ejca.2011.06.046. Epub 2011 Jul 23.

PMID:
21784628
14.

Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.

Qi H, Jiang S, Yu D, Ni H, Hu Q, Zhang J.

Med Oncol. 2015 Dec;32(12):256. doi: 10.1007/s12032-015-0704-x. Epub 2015 Oct 23.

PMID:
26496741
15.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.

Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.

PMID:
26349474
16.

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.

Li W, Ren S, Li J, Li A, Fan L, Li X, Zhao C, He Y, Gao G, Chen X, Li S, Shi J, Zhou C, Fei K, Schmid-Bindert G.

Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.

PMID:
24685306
17.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.

Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.

PMID:
23559152
18.

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.

Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.

PMID:
25617986
19.

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Ou SH, Soo RA.

Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Review.

20.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23.

PMID:
24768581

Supplemental Content

Support Center